Precision Immunotherapy in Axial SpA
Dr. Marina Magrey at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →What's hot
View all perspectives
What's Hot
PsA: Impact of Sex
Dr. Arthur Kavanaugh discusses abstracts 1709 and 1471, along with a related seminar, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
A Fibroblast Renaissance
Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read more →
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome
Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS), presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Say Goodbye to Methotrexate in PMR?
For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.
Read more →
Predicting Flares in Rheumatoid Arthritis
Dr. Jonathan Kay interviews Dr. John Isaacs about abstract 1349, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Read more →
Eric Dein ericdeinmd
1 year 1 month ago
US biosimilar exp
Interchangeable biosimilar - can substitute for reference product wo consulting MD
Primary endpt: pharmacokinetic data
61 approved biosimilars
@RheumKay: “pts should share in financial benefits”
Currently 5-87% discount
#PBMReform @ACRheumDC
@RheumNow #ACR24 https://t.co/RqwbZalZko
sheila RHEUMarampa
1 year 1 month ago
In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%)
This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts.
@rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I
Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl
Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes
Key findings:
- Significant weight loss after starting IL17i, IL23i, and csDMARDs.
- TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn
Caoilfhionn Connolly CaoilfhionnMD
1 year 1 month ago
#2286🔬Certolizumab Pegol (CZP) in High RF RA
📊Pooled analysis;N=1180
💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%)
💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%)
#ACR24 @RheumNow https://t.co/koel7SDsUb
Richard Conway RichardPAConway
1 year 1 month ago
Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu
Richard Conway RichardPAConway
1 year 1 month ago
Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR
Akhil Sood MD AkhilSoodMD
1 year 1 month ago
Long COVID outcomes in Autoimmune diseases (AID)
Abstract 1897:
- Long COVID symptoms higher among AID pts vs controls
- vaccinated may have protective benefit
@RheumNow #ACR24 https://t.co/2SEcbkxfcU
Akhil Sood MD AkhilSoodMD
1 year 1 month ago
Abstract 1915: Barriers to repro health discussions in rheumatology clinic
- Spanish speaking & IA patients report language differences + OB/GYN deferrals as barriers
Appointment time, clinician knowledge, or patient comfort did not make a difference
@RheumNow #ACR24
Mike Putman EBRheum
1 year 1 month ago
Important study in SLE: out of 590 pts with pericarditis, 20% had recurrence w/in 1 year
Higher in early dx, younger pts, higher dx activity, & pred exposure
Is prednisone risk confounding by indication? Or causative?
#ACR24 @RheumNow @andreafava Abstr#2372 https://t.co/Seyi4F6weY
Eric Dein ericdeinmd
1 year 1 month ago
@DianeLacaille Canadian biosimilar exp
Biosimilar transition v originator controls x2 yrs
Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif
Safety- no difference, slight incr rheum visits
@RheumNow #ACR24 https://t.co/0GMfLAyzOo
Richard Conway RichardPAConway
1 year 1 month ago
Ren et al. XG005, compound with NSAID and neuropathic like effects, in knee OA. At week 4 significant improvements in WOMAC pain, stiffness, function, and primary endpoint of walking pain @RheumNow #ACR24 Abstr#L08 https://t.co/gQDwAmzI4G https://t.co/b22XC7rXnE
Mike Putman EBRheum
1 year 1 month ago
Depressing finding re:glucocorticoid discontinuation in SLE
No improvement over decades in rate of GC discontinuation; if anything, we start more GC than ever
@AliDuarteMD help me out here; why haven't we made more progress?
#ACR24 @RheumNow Abstr#2421 https://t.co/uzZATKPWVC
Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
A study evaluating the effectiveness of Direct-to-Patient (D2P) screening for psoriatic arthritis (PsA) in psoriasis patients.
Key findings:
- 30% response rate from 825 patients; 13% screened positive.
- 75% of referrals deemed appropriate, with one-third receiving a new PsA… https://t.co/bcQN6KkC8m https://t.co/zogI2PYvtO
Poster Hall